Entero Therapeutics Inc.
13F holders, Q2 2024 (June 30)8holders +2
2new positions
0sold out
$1.23avg. 13F price*
At the end of Q2 2024, 8 institutions reported holding Entero Therapeutics Inc. in their 13F filings, up 2 from Q1 2024. 2 opened new positions and 0 sold out. The largest holders were Armistice Capital, LLC ($155K), Geode Capital Management, LLC ($20K) and Tower Research Capital LLC (TRC) ($7K).
- Company
- Entero Therapeutics Inc.
- CUSIP
- 33749P408
- Latest filing quarter
- Q2 2025
History
Number of 13F holders
Total Exit/New Position Q1 2024 → Q2 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 2 | $579 |
| Exits | 0 | $0 |
All 13F filers, Q1 2024 → Q2 2024: 107,858 shares bought and 12 shares sold, net +107,846 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 8 holders
| Armistice Capital, LLC | 0.00% | Add +366.7% | 126,000 | $155K |
| Geode Capital Management, LLC | 0.00% | Add +48.9% | 16,146 | $20K |
| Tower Research Capital LLC (TRC) | 0.00% | Add +129.0% | 5,481 | $7K |
| UBS Group AG | 0.00% | New | 449 | $552 |
| Bank of America Corp. | 0.00% | New | 22 | $27 |
| US Bancorp \de | 0.00% | No change | 1 | $1 |
| Wells Fargo & Company | 0.00% | Reduce -92.3% | 1 | $1 |
| Kathleen S. Wright Associates Inc. | 0.00% | No change | 1 | $1 |
"% of holder's portfolio" is ENTERO THERAPEUTICS INC's weight in each manager's 13F, not the share of Entero Therapeutics Inc. the manager owns.